The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 951-962

  Contri, Renata V ^a   Frank, Luiza A ^a   Kaiser, Moacir ^a   Pohlmann, Adriana R ^a   Guterres, Silvia S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Capsaicinoids; Chitosan; Nanocapsules; Skin irritation; Skin permeation

Indexed keywords

ANALGESIC AGENT; CAPSAICIN; CAPSAICINOID; CHITOSAN; DIHYDROCAPSAICIN; NANOCAPSULE; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; HYDROGEL; IRRITANT AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; NANOENCAPSULATION; OUTCOME ASSESSMENT; PH MEASUREMENT; SENSORY ANALYSIS; SKIN EXAMINATION; SKIN IRRITATION; SKIN PERMEABILITY; SKIN WATER LOSS; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHEMISTRY; ERYTHEMA; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; CAPSAICIN; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DERMATOLOGIC AGENTS; ERYTHEMA; FEMALE; HUMANS; HYDROGELS; IRRITANTS; MALE; MIDDLE AGED; NANOCAPSULES; NANOMEDICINE; NANOTECHNOLOGY; YOUNG ADULT;

EID: 84896862677     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S56579     Document Type: Article

References (33)

1. Schaffazick SR, Guterres SS, Freitas LL, Pohlmann AR. Physicochemical characterization and stability of the polymeric nanoparticle systems for drug administration. Quím Nova. 2003;26:726-737.
2. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385:113-142.
3. Mohanraj VG, Chen Y. Nanoparticles: a review. Trop J Pharm Res. 2006;5:561-573.
4. Fontana MC, Rezer JF, Coradini K, Leal DB, Beck RC. Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate. Eur J Pharm Biopharm. 2011;79:241-249.
5. Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules for cutaneous applications. Drug Target Insights. 2007;2:147-157.
6. Contri RV, Fiel LA, Pohlmann AR, Guterres SS, Beck RC. Transport of substances and nanoparticles across the skin and in vitro models to evaluate skin permeation and/or penetration. In: Beck R, Guterres SS, Pohlmann AR, editors. Nanocosmetics and Nanomedicines: New Approaches for Skin Care. Berlin, Germany: Springer; 2011.
7. Castro GA, Coelho AL, Oliveira CA, Mahecha GA, Oréfice RL, Ferreira LA. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm. 2009;38:77-83.
8. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345: 163-171.
9. Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm. 2010;398:165-178.
10. Hayman M, Kam PCA. Capsaicin: a review of its pharmacology and clinical applications. Curr Anaesth Crit Care. 2008;19:338-343.
11. Zi P, Yang XH, Kuang HF, Yang YS, Yu LL. Effect of HP beta CD on solubility and transdermal delivery of capsaicin through rat skin. Int J Pharm. 2008;358:151-158.
12. US Food and DrugAdministration. Capsaicin 8% patch for the management of neuropathic pain associated with human immunodeficiency virus-associated peripheral neuropathy. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ UCM290279.pdf. Accessed November 17, 2013.
13. Barceloux DG. Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Toxic Plants, and Venomous Animals. Hoboken, NJ, USA: John Wiley & Sons; 2008.
14. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) therapy for pain relief - farewell or revival? Clin J Pain. 2008;24: 142-154.
15. Contri RV, Kaiser M, Poletto FS, Pohlmann AR, Guterres SS. Simultaneous control of capsaicinoids release from polymeric nanocapsules. J Nanosci Nanotechnol. 2011;11:2398-2406.
16. Contri RV, Katzer T, Pohlmann AR, Guterres SS. Chitosan hydrogel containing capsaicinoids-loaded nanocapsules: an innovative formulation for topical delivery. Soft Materials. 2010;8:370-385.
17. Contri RV, Katzer T, Ourique AF, et al. Combined effect of polymeric nanocapsules and chitosan hydrogel on the effect of capsaicinoids adhesion to the skin surface. J Biomed Nanotechnol. 2014;10: 725-743.
18. Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81:463-469.
19. Wang JJ, Zeng ZW, Xiao, RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765-774.
20. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:R1-R4.
21. Santos SS, Lorenzoni A, Ferreira LM, et al. Clotrimazole-loaded Eudragit® RS100 nanocapsules: preparation, characterization and in vitro evaluation of antifungal activity against Candida species. Mater Sci Eng C Mater Biol Appl. 2013;33:1389-1394.
22. Katzer T, Pohlmann AR, Guterres SS, Beck RC. Development and optimization of polymeric nanocapsules intended for ophthalmic administration. Abstract presented at the XII International Macromolecular Colloquium, Gramado, Brazil, September 7-10, 2010.
23. Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for transdermal delivery. Int J Nanomedicine. 2010;5:117-128.
24. Rinaudo M. Chitin and chitosan: properties and applications. Prog Polym Sci. 2006;31:603-632.
25. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006;19: 296-302.
26. Cross SE, Jiang RY, Benson HA, Roberts MS. Can increasing the viscosity of formulations be used to reduce the human skin penetration of the sunscreen oxybenzone? J Invest Dermatol. 2001;117:147-150.
27. Green BG. Measurement of sensory irritation of the skin. Am J Contact Dermat. 2000;11:170-180.
28. Lee E, An S, Choi D, Moon S, Chang I. Comparison of objective and sensory skin irritations of several cosmetic preservatives. Contact Dermatitis. 2007;56:131-136.
29. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135-145.
30. Yow HN, Wu X, Routh AF, Guy RH. Dye diffusion from microcapsules with different shell thickness into mammalian skin. Eur J Pharm Biopharm. 2009;72:62-68.
31. Lee CK, Uchida T, Kitagawa K, Yagi A, Kim NS, Goto S. Effect of hydrophilic and lipophilic vehicles on skin permeation of tegafur, alclofenac and ibuprofen with or without permeation enhancers. Biol Pharm Bull. 1993;16:1264-1269.
32. Hatanaka T, Katayama K, Koizumi T, Sugibayashi K, Morimoto Y. Time-dependent percutaneous-absorption enhancing effect of ethanol. J Control Release. 1995;33:423-428.
33. Magnusson BM, Koskinen LOD. In vitro percutaneous penetration of topically applied capsaicin in relation to in vivo sensation responses. Int J Pharm. 2000;195:55-62.